Apellis Pharmaceuticals (APLS) Set to Announce Quarterly Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) will release its earnings data before the market opens on Tuesday, May 7th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.55) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73). The business had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The business’s revenue for the quarter was up 545.9% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.50) earnings per share. On average, analysts expect Apellis Pharmaceuticals to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $47.46 on Monday. The company has a market cap of $5.76 billion, a price-to-earnings ratio of -10.59 and a beta of 0.97. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75. The company has a fifty day simple moving average of $55.71 and a two-hundred day simple moving average of $57.53.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on APLS shares. The Goldman Sachs Group increased their price target on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. Raymond James lifted their price target on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a report on Thursday, January 11th. JPMorgan Chase & Co. increased their target price on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Wedbush dropped their price objective on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, Jefferies Financial Group raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the company from $68.00 to $80.00 in a research report on Monday, February 5th. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $77.40.

Insider Activity

In other news, CFO Timothy Eugene Sullivan sold 1,431 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $96,978.87. Following the sale, the chief financial officer now owns 93,338 shares of the company’s stock, valued at approximately $6,325,516.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, General Counsel David O. Watson sold 781 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $52,928.37. Following the completion of the sale, the general counsel now directly owns 103,390 shares in the company, valued at $7,006,740.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Timothy Eugene Sullivan sold 1,431 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $96,978.87. Following the sale, the chief financial officer now owns 93,338 shares in the company, valued at approximately $6,325,516.26. The disclosure for this sale can be found here. Insiders sold 376,427 shares of company stock valued at $23,169,639 in the last three months. 7.50% of the stock is currently owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).